FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to an ophthalmic product, which is a hermetically sealed aqueous solution in which a contact lens is placed for storage. Lens contains a composition comprising an ester or amide of an anti-inflammatory lipoid mediator which is a reaction product of an anti-inflammatory lipoid mediator and a monohydric alcohol or amine, where the ester is selected from a group consisting of an esterified polyunsaturated fatty acid selected from Omega-3 and Omega-6 fatty acids, and where composition contains 10 % by weight or less of the acid form of the anti-inflammatory lipoid mediator, and wherein, in addition, the aqueous solution is selected from saline, a buffer solution and water.
EFFECT: invention enables to obtain an ophthalmic product, which is a hermetically sealed aqueous solution, in which a contact lens is placed for storage.
13 cl, 11 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ESTERS FOR TREATMENT OF OPHTHALMOLOGICAL INFLAMMATORY DISEASES | 2012 |
|
RU2640506C9 |
| ESTERS FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISEASES | 2012 |
|
RU2747953C2 |
| COMPOUND ETHERS FOR TREATMENT OF OPHTHALMOLOGICAL INFLAMMATORY DISEASES | 2012 |
|
RU2673230C1 |
| ESTERS FOR OPHTHALMOLOGICAL INFLAMMATORY DISEASES TREATMENT | 2012 |
|
RU2627438C2 |
| COMPOSITIONS BASED ON PARTIALLY FLUORINATED ALKANES, CONTAINING ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | 2019 |
|
RU2808451C2 |
| COMPOSITIONS AND METHODS FOR TREATING EYE DISORDERS | 2020 |
|
RU2795913C2 |
| COMPOSITIONS AND METHODS OF TREATING EYE DISORDERS | 2020 |
|
RU2802625C2 |
| PHARMACEUTICAL FORMULATIONS OF NON-POLAR AND POLAR LIPIDS FOR OPHTHALMOLOGICAL APPLICATION | 2007 |
|
RU2495661C2 |
| STABILIZED OPHTHALMIC COMPOSITIONS CONTAINING OMEGA-3-ACIDS | 2015 |
|
RU2697844C2 |
| LIPID-BASED OPHTHALMIC EMULSION | 2019 |
|
RU2793333C2 |
